Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours: Tovey SM, Brown S, Doughty JC, et al (Glasgow Royal Infirmary, United Kingdom) Br J Cancer 100:680-683, 2009§

[1]  E. Mallon,et al.  Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours , 2008, British Journal of Cancer.

[2]  A. Gown,et al.  Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Gelber,et al.  Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. , 2008, The Lancet. Oncology.

[4]  G. Hortobagyi,et al.  Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[6]  H. Burstein,et al.  The distinctive nature of HER2-positive breast cancers. , 2005, The New England journal of medicine.

[7]  Terry L. Smith,et al.  Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[9]  H. D. de Koning,et al.  Decreased rates of advanced breast cancer due to mammography screening in The Netherlands , 2004, British Journal of Cancer.

[10]  S. Chia,et al.  Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Mikael Lundin,et al.  Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  J. Myles,et al.  HER2/neu amplification in breast cancer: stratification by tumor type and grade. , 2002, American journal of clinical pathology.

[13]  Donald L Weaver,et al.  Increased mammography use and its impact on earlier breast cancer detection in Vermont, 1975–1999 , 2002, Cancer.

[14]  D. Hayes,et al.  When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[16]  P. Ravdin,et al.  The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. , 1995, Gene.

[17]  L. Norton,et al.  Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  G. Kornek,et al.  Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. , 1992, Surgery, gynecology & obstetrics.

[19]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.